A5022308801- Chronic Lymphocytic Leukemia Research
- Lymphoma Diagnosis and Treatment
- Immunodeficiency and Autoimmune Disorders
- Multiple Myeloma Research and Treatments
- Viral-associated cancers and disorders
- Acute Lymphoblastic Leukemia research
- Acute Myeloid Leukemia Research
- Protein Degradation and Inhibitors
- Galectins and Cancer Biology
- Peptidase Inhibition and Analysis
- Chronic Myeloid Leukemia Treatments
- Advanced Breast Cancer Therapies
- CNS Lymphoma Diagnosis and Treatment
- Neuroendocrine Tumor Research Advances
- Platelet Disorders and Treatments
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Glycosylation and Glycoproteins Research
- Blood groups and transfusion
- SARS-CoV-2 and COVID-19 Research
- Lung Cancer Treatments and Mutations
- Amyloidosis: Diagnosis, Treatment, Outcomes
- Cutaneous lymphoproliferative disorders research
- CAR-T cell therapy research
- Gastrointestinal Tumor Research and Treatment
- Autoimmune Bullous Skin Diseases
Inserm
2014-2025
Université de Poitiers
2014-2025
Centre Hospitalier Universitaire de Poitiers
2014-2023
Bristol-Myers Squibb (United States)
2019
Kantar Health (United States)
2019
National Marrow Donor Program
2019
Laboratoire de Génétique Cellulaire
2016-2017
Institut Gustave Roussy
2014
Université Paris-Sud
2014
Laboratoire d'études sur les monothéismes
2014
Rituximab/chemotherapy is a cornerstone of treatment for Waldenström's macroglobulinemia (WM). In addition, bortezomib has shown significant activity in WM. This study evaluated the efficacy and safety dexamethasone, rituximab, cyclophosphamide (DRC) as first-line WM.In this European study, treatment-naïve patients were randomly assigned to DRC or bortezomib-DRC B-DRC six cycles. The primary end point was progression-free survival. Secondary points included response rates, overall survival,...
Purpose:TP53 is a tumor-suppressor gene that functions as regulator influencing cellular responses to DNA damage, and TP53 alterations are associated with pejorative outcome in most B-lymphoid disorders. Little known regarding alteration Waldenstrom's macroglobulinemia (WM).Experimental Design: Here, we have explored the incidence of using Sanger sequencing ultradeep-targeted 125 WM 10 immunoglobulin M (IgM) monoclonal gammopathy undetermined significance (MGUS), along clinical features...
Richter syndrome (RS) is the transformation of chronic lymphocytic leukemia (CLL) into aggressive lymphoma, most commonly diffuse large B-cell lymphoma (DLBCL). We characterize 58 primary human RS samples by genome-wide DNA methylation and whole-transcriptome profiling. Our comprehensive approach determines profile unravels a CLL epigenetic imprint, allowing CLL-RS clonal relationship assessment without need initial tumor DNA. methylation- transcriptomic-based classifiers were developed,...
Summary A large, multicentre, retrospective survey of patients with hairy cell leukaemia ( HCL ) was conducted in France to determine the frequency second malignancies and analyse long‐term effects established purine nucleoside analogues PNA s), cladribine pentostatin. The retrospectively reviewed medical history their immediate family, clinical biological presentation at time diagnosis, treatment choice, response treatment, relapse cause death. Data were collected for 487 . Of included...
In total, 279 patients with hairy-cell leukemia (HCL) were analyzed, a median follow-up of 10 years. Data collected up to June 2018. We analyzed responses treatment, relapses, survival, and the occurrence second malignancies during follow-up. The age was 59 208 (75%) treated purine analogs (PNAs), either cladribine (159) or pentosatin (49), as first-line therapy. After 127 months, overall survival 27 years, relapse-free (RFS) 11 cumulative 10-year relapse incidence 39%. receiving second-line...
Summary Histological transformation ( HT ) to diffuse large B‐cell lymphoma DLBCL is a rare and poorly reported complication of Waldenström macroglobulinaemia WM ). We performed retrospective study 77 patients with biopsy‐proven . The median time from diagnosis was 4·6 years 16 (21%) had never been treated for At , extranodal sites were observed in 91% rather high incidence central nervous system, cutaneous or testicular involvement. Fluorodeoxyglucose‐positron emission tomography half the...
Abstract We present the results of a phase 2 study evaluating combination obinutuzumab + idelalisib in relapsed/refractory (R/R) Waldenström macroglobulinemia (WM). The goal was to determine safety and efficacy fixed-duration chemotherapy-free treatment. During induction phase, patients received for 6 cycles, followed by maintenance with alone ≤2 years. Forty-eight R/R WM were treated combination, 27 participated phase. best responses, reached after median 6.5 months (interquartile range,...
Hairy cell leukemia (cHCL) patients have, in most cases, a specific clinical and biological presentation with splenomegaly, anemia, leukopenia, neutropenia, monocytopenia and/or thrombocytopenia, identification of hairy cells that express CD103, CD123, CD25, CD11c the V600E mutation B-Raf proto-oncogene (BRAF) 90% cases. Monocytopenia is absent vHCL SDRPL abnormal do not CD25 or CD123 present BRAFV600E mutation. Ten percent cHCL are BRAFWT distinction between HCL-like disorders including...
Key Clinical Message 18 F‐FDG PET/CT has clinical relevance in HCL at diagnosis and for the follow‐up of patients treated, especially case atypical presentations such as bone involvements (which are probably underestimated) poor marrow infiltration. Abstract Bone lesions rarely reported Hairy Cell Leukemia (HCL). We report two BRAF V600E mutated presented foreground, involvement, important role played their management. discuss crucial that could play routine practice.
The optimal management of patients with relapsed chronic lymphocytic leukemia (CLL) is dictated by the type prior therapy, duration response, presence genomic aberrations, age, and comorbidities. patterns relapses clinical outcomes second-line options after fludarabine-cyclophosphamide-rituximab (FCR) given as a frontline treatment are currently unknown. In this retrospective non-randomized study, we report 132 from databases 14 French CLL study group centers who needed FCR frontline....
Histological transformation into diffuse large B-cell lymphoma is a rare complication in patients with Waldenström macroglobulinemia (WM) and usually associated poor prognosis. The objective of this study was to develop validate prognostic index for survival transformed WM. Through multicenter, international collaborative effort, we developed scoring system based on data from 133 WM who were evaluated between 1995 2016 (training cohort). Univariate multivariate analyses used propose 2-year...
Hairy-cell leukemia (HCL) is a rare B-cell chronic lymphoproliferative disorder (B-CLPD), whose favorable prognosis has changed with the use of purine nucleoside analogs (PNAs), such as cladribine (CDA) or pentostatin (P). However, some patients eventually relapse and over time HCL becomes resistant to chemotherapy. Many discoveries have been made in pathophysiology during last decade, especially genomics, identification BRAFV600E mutation cellular biology, including importance signaling...
As ibrutinib has become a standard of care in B-cell malignancies monotherapy or combination with other agents, definition its safety profile appears essential. The aim this study was to further characterize the through identification potential signals large-scale pharmacovigilance database. All serious individual case reports (ICSRs) patients aged ≥18 years involving suspected occurrence adverse drug reactions interacting from November 13th, 2013 December 31st, 2020 were extracted VigiBase,...
Abstract In previously untreated, medically fit patients with chronic lymphocytic leukemia (CLL), research is focused on developing fixed-duration strategies to improve long-term outcomes while sparing from serious toxicities. The ICLL-07 trial evaluated a (15-month) immunochemotherapy approach in which after obinutuzumab-ibrutinib induction for 9 months, (n = 10) complete remission (CR) bone marrow (BM) measurable residual disease (MRD) <0.01% continued only ibrutinib 420 mg/day 6...